News & Updates

Show Multimedia Only

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

20 Nov 2025 by

A 69-year-old female diagnosed with localized stage T1b cholangiocarcinoma underwent an extended left hepatectomy with focally involved resection margins in April 2020. Adjuvant therapy was omitted due to prolonged postoperative intra-abdominal sepsis. She remained disease-free until December 2021, when a follow-up CT scan revealed a suspicious 6 mm lesion in liver segments 7/8. A subsequent CT scan in August 2022 showed interval enlargement of the lesion, confirming liver metastasis.

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

20 Nov 2025

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

20 Nov 2025 by

When treating hormone receptor–positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC), it is important to target the oestrogen receptor (ER) pathway for as long as the disease remains endocrine-sensitive. In an interview with MIMS Oncology, Dr Shaheenah Dawood, Head of the Oncology Clinical Trials Programme and Director of Oncology Services at Mediclinic City Hospital, Dubai, United Arab Emirates, described how co-targeting both the PI3K/AKT/mTOR and ER pathways with capivasertib and fulvestrant optimizes endocrine therapy (ET) to benefit patients with PIK3CA/AKT1/PTEN-altered HR+/HER2- mBC.

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

20 Nov 2025

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

15 Nov 2025 by

Pathological complete response (pCR) to earlier therapy is one of the key prognostic factors in patients with HER2-positive (HER2+) breast cancer (BC), which can help inform subsequent treatment decisions. In an interview with MIMS Oncology, Dr Joyce Lee, Specialist in Oncology in private practice in Hong Kong, discusses pCR and factors associated with disease recurrence, as well as data supporting the use of neratinib, an irreversible, small-molecule pan-HER tyrosine kinase inhibitor (TKI), as extended adjuvant therapy in hormone receptor– positive (HR+)/HER2+ BC.

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

15 Nov 2025

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

14 Nov 2025 by

Lung cancer remains the most common cancer and a leading cause of cancer-related mortality, with improved but still suboptimal survival outcomes despite advances in treatment. At a recent symposium chaired by Dr Shi-Feng Nyaw, Specialist in Clinical Oncology, Hong Kong, Professor Tianqing Chu, Consultant at the Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China, highlighted how tislelizumab, a novel immunotherapy agent, differs from other anti–programmed death receptor 1 (PD-1) therapies. She presented efficacy and safety data for tislelizumab in both squamous and non-squamous non-small-cell lung cancer (NSCLC) from RATIONALE-307/304 and her routine clinical practice. Additionally, Professor Victor Lee, Clinical Professor at the Department of Clinical Oncology, The University of Hong Kong, shared real-world cases illustrating the clinical benefits of tislelizumab in NSCLC patients.

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

14 Nov 2025

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

29 Oct 2025

The phase I/II TRIDENT-1 trial demonstrates high ORR and durable activity of repotrectinib, a next-generation TKI, in TKI-naïve and -pretreated ROS1+ or NTRK1–3+ locally advanced or metastatic NSCLC, including patients from Asia.

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

29 Oct 2025

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

25 Oct 2025 by

A 70-year-old woman with stage 2A triple-negative breast cancer (TNBC; pT1cN1a) and excellent performance status (PS) underwent left total mastectomy followed by adjuvant chemotherapy. Genetic testing revealed no germline BRCA1/2 mutations. Three years later, she developed neck and upper limb swelling. Left neck biopsy confirmed triple-negative metastatic disease with PD-L1 combined positive score (CPS) >75. She received weekly paclitaxel and pembrolizumab, achieving a good response. After 21 cycles (approximately 1.5 years), she developed a sternal nodule, which was surgically excised; pathology indicated triple-negative grade 3 invasive carcinoma with extensive lymphovascular invasion. Molecular testing showed no targetable mutations.

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

25 Oct 2025

Blinatumomab for B-cell precursor ALL: From hospital to home

24 Oct 2025 by

Blinatumomab, a bispecific T cell–engager antibody administered as a continuous intravenous (IV) infusion, has several indications in B-cell precursor acute lymphoblastic leukaemia (ALL). Traditionally, in Hong Kong, patients receiving blinatumomab are hospitalized for 28-day treatment cycles. In an interview with MIMS Oncology, Dr Carol Cheung, Specialist in Haematology & Haematological Oncology, and clinical pharmacist Ms Kitty Leung shared insights into how a proactive outpatient infusion protocol at a local hospital has enabled patients to receive blinatumomab at home. They discussed how home infusion of blinatumomab works, along with its risks, challenges, and benefits for both patients and healthcare providers.

Blinatumomab for B-cell precursor ALL: From hospital to home

24 Oct 2025

Use of a MET inhibitor in a patient with newly diagnosed advanced NSCLC with METex14 skipping mutation

23 Oct 2025 by

An 80-year-old Chinese male, a long-term smoker with no significant medical history, was found to have a right lung mass on a routine chest X-ray in August 2021. A CT scan of the chest revealed a dominant right lower lobe mass (3.3 x 2.3 x 2.7 cm) with multiple bilateral lung nodules. CT-guided fine needle aspiration cytology (FNAC) of the right lower lobe mass performed on 2 December 2021 confirmed adenocarcinoma, while a PET-CT scan on 10 January 2022 showed a right lower lobe tumour with metastases to the left hilar and mediastinal lymph nodes and both lungs. (Figure 1A) Next-generation sequencing (OncoSnap Nonet) identified MET exon 14 (METex14) skipping mutation. The programmed death ligand 1 (PD-L1) tumour proportion score (TPS) was 0 percent. The patient was diagnosed with stage IV non-small-cell lung cancer (NSCLC) harbouring a METex14 skipping mutation. His Eastern Cooperative Oncology Group performance status (ECOG PS) was 0.

Use of a MET inhibitor in a patient with newly diagnosed advanced NSCLC with METex14 skipping mutation

23 Oct 2025

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

23 Oct 2025 by

Concurrent chemoradiotherapy (cCRT) has long been the standard curative-intent treatment for stage III unresectable non-small-cell lung cancer (NSCLC) and limited-stage (LS) small-cell lung cancer (SCLC). Following cCRT, consolidation therapy with durvalumab, an anti–PD-L1 antibody, is considered the standard-of-care (SoC) for patients with stage III NSCLC with no actionable genomic alterations. However, uncertainty exists on consolidation therapy options with EGFR tyrosine kinase inhibitors (TKIs) for patients with EGFR-mutant NSCLC, given the established evidence supporting their use in both resectable and unresectable stages, as well as in LS-SCLC. At an industry-sponsored symposium, Professor Te-Chun Hsia of the China Medical University Hospital in Taichung, Taiwan, discussed evolving consolidation therapy strategies in lung cancer, highlighting the role of osimertinib, a third-generation EGFR TKI, in patients with unresectable stage III EGFR-mutated NSCLC, and durvalumab in those with LS-SCLC.

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

23 Oct 2025

PSMA-targeted radioligand therapy improves survival in patients with mCRPC

10 Oct 2025 by

A 63-year-old male with hypertension, hyperlipidaemia and diabetes was diagnosed with metastatic prostate cancer with lumbar spine metastases in 2018. He initially presented with lower urinary tract symptoms and markedly elevated prostate-specific antigen (PSA) of up to 85.3 ng/mL. He was started on luteinizing hormone–releasing hormone (LHRH) antagonist as androgen deprivation therapy (ADT) with good response of PSA drop to 13.4 mg/mL.

PSMA-targeted radioligand therapy improves survival in patients with mCRPC

10 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives

Blinatumomab for B-cell precursor ALL: From hospital to home

Blinatumomab for B-cell precursor ALL: From hospital to home

Use of a MET inhibitor in a patient with newly diagnosed advanced NSCLC with METex14 skipping mutation

Use of a MET inhibitor in a patient with newly diagnosed advanced NSCLC with METex14 skipping mutation

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

PSMA-targeted radioligand therapy improves survival in patients with mCRPC

PSMA-targeted radioligand therapy improves survival in patients with mCRPC